Dr. Rahul Kushwah reports

QSCREEN AI SECURES SECOND US PATENT, EXTENDING SINGLE-CAMERA IMPAIRMENT DETECTION ON STANDARD HARDWARE

QScreen AI Inc. holds two granted U.S. patents covering its core impairment detection method after the U.S. Patent and Trademark Office granted the company U.S. patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026. The new grant extends the company's protection to impairment detection from a single camera on standard, already-deployed hardware, the form factor institutional buyers are most likely to adopt.

The company has been building this patent estate since 2019, and the same inventive team is named on both grants. Its first patent, U.S. 11,670,323 B2, granted in June, 2023, required two or more images of different parts of a person to detect impairment. The second patent granted protects the same underlying method from as few as a single image, with the earlier multi-image and audio-based approaches preserved in the dependent claims.

The significance is both commercial and competitive. A granted method patent gives its owner the right to exclude others from practising that method. Taken together, the two patents bracket the deployment spectrum: The first covers multicamera arrangements, and the currently granted patent extends the same method to a single camera on commodity hardware. The company therefore holds patented protection over the lightweight deployment that correctional health, defence, transportation and industrial safety buyers actually want, screening that runs on a laptop or tablet already on site, with no new hardware and no installation project. Competitors seeking to offer camera-based impairment screening on standard devices must contend with the company's granted claims.

The patented method is the foundation of QScreen's screening platform, which reads physiological, acoustic and behavioural signals to produce a readiness assessment on existing hardware and routes it to a trained supervisor or licensed professional for the decision.

Dr. Rahul Kushwah, chief operating officer of QScreen AI, stated: "We have spent six years building this patent estate, and this is the grant that matters most. Owning the method from a single camera, not just a multicamera rig, means our protection now covers the exact way institutions want to deploy this -- on hardware they already own. We are commercializing from a defended position, and that is a very different place to build from than an idea without a moat."

The grant lands as the company advances its previously announced commercial outreach. Through its engagement with Global Frontier Advisors, led by Lt.-Gen. Michael S. Groen (retired), former director of the U.S. Department of Defence Joint Artificial Intelligence Center and a QScreen adviser, the company is in structured discussions across U.S. correctional health and defence verticals, and has commenced direct outreach to provincial correctional health authorities in Canada. Advisory board member Jose (Beto) Vargas Garcia, former vice-president at Union Pacific, supports the company's engagement across North American rail and logistics. A first signed evaluation agreement remains the stated near-term milestone, and the company believes a broadened, granted patent estate strengthens its position in each of these conversations.

About QScreen AI Inc.

QScreen AI is a health-technology company developing artificial-intelligence-based physiological screening for readiness and impairment across institutional and workplace settings, built on a foundation of two granted U.S. patents. The platform is designed to run on standard hardware and to support fitness-for-duty and intake decisions, with every decision made by a qualified person.

We seek Safe Harbor.